<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1801221612
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CLARIDAR
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAR ALDAWA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> Tablet contains 250 mg or 500 mg of the active ingredient clarithromycin.</p><p><strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> belongs to a group of medicines called macrolide antibiotics. Antibiotics stop the growth of bacteria (bugs) which cause infections.</p><p><strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> Tablets are used to treat infections such as:</p><p>- Chest infections such as bronchitis and pneumonia</p><p>-Throat and sinus infections</p><p>- Skin and tissue infections</p><p>- <em>Helicobacter pylori </em>infection associated with duodenal ulcer</p><p><strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> Tablets are indicated in adults and children 12 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use<strong> Claridar Dar Al Dawa<sup>&reg; </sup>if you:</strong></p><p>- know that you are allergic to clarithromycin, other macrolide antibiotics such as erythromycin or azithromycin, or any of the other ingredients in the tablets.</p><p>- Are taking medicines called ergotamine or dihydroergotamine tablets or use ergotamine inhalers for migraine.</p><p>- Are taking medicines called terfenadine or astemizole (widely taken for hay fever or allergies) or cisapride (for stomach disorders) or pimozide (for mental health problems) as combining these drugs can sometimes cause serious disturbances in heart rhythm.</p><p>- Are taking lovastatin or simvastatin (HMG-CoA reductase inhibitors, commonly known as statins, used to lower levels of cholesterol (a type of fat) in the blood).</p><p>- Have low levels of potassium in the blood (a condition known as hypokalaemia).</p><p>- Have severe<strong> </strong>liver disease with kidney disease.</p><p>- Have an irregular heart rhythm.</p><p><strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong><strong> </strong>tablets<strong> </strong>are not suitable for use in children under 12 years of age.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Take special care with</strong><strong> </strong><strong>Claridar Dar Al Dawa<sup>&reg; </sup></strong></p><p>- If you have any liver or kidney problems</p><p>- If you have, or are prone to, fungal infections (e.g. thrush)</p><p>- If you are pregnant or breast feeding</p><p>&nbsp;If any of these apply to you, consult your doctor before taking <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Using other medicines, herbal or dietary supplements</strong></p><p>You should not take <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets if you are taking any of the medicines listed in the section above <strong>&ldquo;Do not take </strong><strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong><strong> tablets if you;&rdquo;</strong></p><p>Tell your doctor if you are taking any of the following medicines as your dose may need to be changed or you may need to have regular tests performed:</p><p>- Digoxin, quinidine or disopyramide (for heart problems).</p><p>- Warfarin (for thinning the blood).</p><p>- Carbamazepine, valproate, phenobarbital or phenytoin (for epilepsy).</p><p>- Atorvastatin, rosuvastatin (HMG-CoA reductase inhibitors, commonly known as statins, and used to lower levels of cholesterol (a type of fat) in the blood).</p><p>- Colchicine (usually taken for gout).</p><p>- Nateglinide, pioglitazone, repaglinide, rosiglitazone or insulin (used to lower blood glucose levels).</p><p>- Theophylline (used in patients with breathing difficulties such as asthma).</p><p>- Triazolam, alprazolam or midazolam (sedatives).</p><p>- Cilostazol (for poor circulation).</p><p>- Omeprazole (for treatment of indigestion and gastric ulcers) unless your doctor has prescribed it for you to treat <em>Helicobacter pylori </em>infection associated with duodenal ulcer.</p><p>- Methylprednisolone (a corticosteroid).</p><p>- Vinblastine (for treatment of cancer).</p><p>- Ciclosporin, sirolimus and tacrolimus (immune suppressants).</p><p>- Etravirine, efavirenz, nevirapine, ritonavir, zidovudine, atazanavir, saquinavir (anti-viral drugs used in the treatment of HIV).</p><p>- Rifabutin, rifampicin, rifapentine, fluconazole, itraconazole (used in the treatment of certain bacterial infections).</p><p>- Tolterodine (for overactive bladder).</p><p>- Verapamil (for high blood pressure).</p><p>- Sildenafil, vardenafil and tadalafil (for impotence in adult males or for use in pulmonary arterial hypertension (high blood pressure in the blood vessels of the lung)).</p><p>- St John&rsquo;s Wort (a herbal product used to treat depression).</p><p><strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> does not interact with oral contraceptives.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy and breast-feeding</p><p>If you are pregnant, think you may be pregnant, or if you are breast-feeding, consult your doctor before taking <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets as the safety of <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets in pregnancy and breast-feeding is not known.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Driving and using machines</p><p><strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets may make you feel dizzy or drowsy. If they affect you in this way do not drive, operate machinery or do anything that requires you to be alert.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not give these tablets to children under 12 years. Your doctor will prescribe another suitable medicine for your child.</p><p>Always take <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. The usual dose is:</p><p><strong>For chest infections, throat or sinus infections and skin and soft tissue infections:</strong></p><p>Usual dose of <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets for adults and children over 12 years is 250 mg twice daily for 6 to 14 days, e.g. one 250 mg tablet in the morning and one in the early evening. Your doctor may increase the dose to 500 mg twice daily in severe infections.</p><p><strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets should be swallowed with at least half a glass of water.</p><p><strong>For the treatment of <em>Helicobacter pylori </em>infection associated with duodenal ulcers:</strong></p><p>There are a number of effective treatment combinations available to treat <em>Helicobacter pylori </em>in which <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets are taken together with one or two other drugs.</p><p>These combinations include the following and are usually taken for 6 to 14 days:</p><p>a) One <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken &nbsp;twice a day plus lansoprazole, 30 mg twice a day.</p><p>b) One <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> 500 mg tablet taken twice a day together with metronidazole, 400 mg taken twice a day plus lansoprazole, 30 mg twice a day.</p><p>c) One <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day or metronidazole, 400 mg taken twice a day plus omeprazole, 40 mg a day.</p><p>d) One <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day plus omeprazole, 20 mg taken once a day.</p><p>e) One <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> 500 mg tablet taken three times a day together with omeprazole 40 mg taken once a day.</p><p>The treatment combination that you receive may differ slightly from the above. Your doctor will decide which treatment combination is the most suitable for you. If you are unsure which tablets you should be taking or how long you should be taking them for, please consult your doctor for advice.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you take more </strong><strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong><strong> than you should</strong></p><p>If you accidentally take more <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets in one day than your doctor has told you to, or if a child accidentally swallows some tablets, contact your doctor or nearest hospital emergency department immediately. An overdose of <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets is likely to cause vomiting and stomach pains.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you use forget to take &nbsp;Claridar Dar Al Dawa<sup>&reg; </sup>&nbsp;tablets</strong></p><p>If you forget to take a <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablet, take one as soon as you remember. Do not take more tablets in one day than your doctor has told you to.</p><p>Do not stop taking <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets, even if you feel better. It is important to take the tablets for as long as the doctor has told you to, otherwise the problem might come back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets can cause side effects although not everybody gets them.</p><p>If you suffer from any of the following at any time during your treatment STOP TAKING your tablets and contact your doctor immediately:</p><p>&bull; Severe or prolonged diarrhoea, which may have blood or mucus in it. Diarrhoea may occur over two months after treatment with clarithromycin, in which case you should still contact your doctor.</p><p>&bull; A rash, difficulty breathing, fainting or swelling of the face and throat. This is a sign that you may have developed an allergic reaction.</p><p>&bull; Yellowing of the skin (jaundice), skin irritation, pale stools, dark urine, tender abdomen or loss of appetite. These may be signs that your liver may not be working properly.</p><p>&bull; Severe skin reactions such as blistering of the skin, mouth, lips, eyes and genitals (symptoms of a rare allergic reaction called Stevens-Johnson syndrome/toxic epidermal necrolysis).</p><p>&bull; Henoch-Schonlein purpura (a rash which appears as purple spots on the skin).</p><p>Common side effects of <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> tablets include:</p><p>&bull; Headache</p><p>&bull; Difficulty sleeping</p><p>&bull; Changes in sense of taste</p><p>&bull; Stomach problems such as feeling sick, vomiting, stomach pain, indigestion, diarrhoea</p><p>&bull; A change in the way your liver works</p><p>&bull; Skin rash</p><p>&bull; Increased sweating</p><p>Other less common side effects include:</p><p>&bull; Swelling, redness or itchiness of the skin. Sometimes brown scales may appear</p><p>&bull; Acne</p><p>&bull; Henoch-Schonlein purpura (a rash which appears as purple spots on the skin)</p><p>&bull; Oral or vaginal &lsquo;thrush&rsquo; (a fungal infection)</p><p>&bull; Reduction in the level of certain blood cells (which can make infections more likely or increase the risk of bruising or bleeding)</p><p>&bull; Loss of appetite, heartburn, bloating, constipation, wind</p><p>&bull; Inflammation of the pancreas</p><p>&bull; Anxiety, nervousness, drowsiness, tiredness, dizziness, tremor or shaking</p><p>&bull; confusion, loss of bearings, hallucinations (seeing things), change in sense of reality or panicking, depression, abnormal dreams or nightmares</p><p>&bull; Convulsion (fits)</p><p>&bull; Ringing in the ears or hearing loss</p><p>&bull; Vertigo</p><p>&bull; Paraesthesia, more commonly known as &lsquo;pins and needles&rsquo;</p><p>&bull; Leaking of blood from blood vessels (haemorrhage)</p><p>&bull; Inflammation of the mouth or tongue</p><p>&bull; Discoloration of the tongue or teeth</p><p>&bull; Dry mouth</p><p>&bull; Loss of taste or smell or inability to smell properly</p><p>&bull; Joint pain</p><p>&bull; Muscle pain or loss of muscle tissue. If you suffer from myasthenia gravis (a condition in which the muscles become weak and tire easily) or rhabdomyolysis (a condition which causes the breakdown of muscle tissue), clarithromycin may worsen these symptoms</p><p>&bull; Chest pain or changes in heart rhythm such as palpitations</p><p>&bull; A change in the levels of products made by the liver, inflammation of the liver or an inability of the liver to function properly (you may notice yellowing of the skin, dark urine, pale stools or itchiness of the skin)</p><p>&bull; A change in the levels of products produced by the kidney, inflammation of the kidney or an inability of the kidney to function properly (you may notice tiredness, swelling or puffiness in the face, abdomen, thighs or ankles or problems with urination)</p><p>&bull; Low blood sugar levels</p><p>&bull; A change in the levels of certain cells or products found in the blood.</p><p>Consult your doctor immediately if you develop any of these problems or have any other unexpected or unusual symptoms.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&minus; Keep out of the reach and sight of children.</p><p>&minus; Store below 30ْC.</p><p>&minus; Do not use <strong>Claridar Dar Al Dawa<sup>&reg; </sup></strong>after the expiry date which is stated on the carton or bottle. The expiry date refers to the last day of that month.</p><p>&minus; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Active ingredient:</p><p>Each <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> 250 film tablet contains 250 mg clarithromycin.</p><p>Each <strong>Claridar Dar Al Dawa<sup>&reg;</sup></strong> 500 film tablet contains 500 mg clarithromycin.</p><p>Other inactive ingredients: Hydroxypropyl cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, microcrystalline cellulose, hypromellose, titanium dioxide, macrogol, talc, simethicone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                - Claridar Dar Al Dawa® 250 tablets are white, round biconvex film-coated tablets coded (CLR250) on one side, plain on the other side. 
- Claridar Dar Al Dawa® 500 tablets are white, oval biconvex film coated tablets coded (CLR500) on one side, plain on the other side. 
Claridar Dar Al Dawa® 250 and Claridar Dar Al Dawa® 500 film coated tablets are available in packs of 14.
Claridar Dar Al Dawa® 500 are also available in packs of 20. 
Not all pack sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dar Al Dawa Development &amp; Investment Co. Ltd. (Na&#39;ur &ndash; Jordan).</p><p>Tel. (+962 6) 57 27 132</p><p>Fax. (+962 6) 57 27 776</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
12/2013

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي كل قرص من <strong>كلاريدار دار الدواء</strong> على 250 أو 500 ملغم من المادة الفعالة كلاريثرومايسين.</p><p dir="RTL">ينتمي <strong>كلاريدار دار الدواء</strong> الى<strong> </strong>مجموعة من الادوية تسمى المضادات الحيوية الماكروليدية. تعمل المضادات الحيوية على وقف نمو البكتيريا (الجراثيم) التي تسبب الالتهابات.</p><p dir="RTL">تستخدم أقراص<strong> كلاريدار دار الدواء </strong>لعلاج الالتهابات مثل:</p><p dir="RTL">- الالتهابات الصدرية مثل التهاب الشعب الهوائية والالتهاب الرئوي</p><p dir="RTL">- التهابات الحلق والجيوب الأنفية</p><p dir="RTL">- التهابات الجلد والأنسجة</p><p dir="RTL">- عدوى <em>هيليكوباكتر بيلوري</em> المرتبطة بقرحة الاثني عشر</p><p>تستخدم أقراص <strong>كلاريدار دار الدواء</strong> في البالغين والأطفال 12 سنة وما فوق</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع</strong><strong> </strong><strong>استعمال </strong><strong>&nbsp;</strong><strong>كلاريدار دار الدواء</strong></p><p dir="RTL">- &nbsp;فرط الحساسية تجاه كلاريثرومايسين أو المضادات الحيوية الماكروليدية الأخرى مثل اريثروميسين أو أزيثروميسين، أو أي من المكونات الأخرى في الأقراص.</p><p dir="RTL">- اذا كنت تتناول أقراص تحتوي على الإرغوتامين أو ثنائي هيدروأرغوتامين أو تستخدم علاج استنشاق يحتوي على الإرغوتامين لعلاج الصداع النصفي.</p><p dir="RTL">- اذا كنت تتناول أدوية تسمى تيرفينادين أو استيمايزول (يستخدم غالبا في علاج حمى القش أو الحساسية) أو سيسابريد (لاضطرابات المعدة) أو بيموزيد (للاضطرابات العقلية) ، حيث أن الجمع بين هذه الادوية &nbsp;قد يسبب أحيانا اضطرابات خطيرة في معدل ضربات القلب.</p><p dir="RTL">- اذا كنت تتناول لوفاستاتين أو سيمفاستاتين ( أدوية مثبطة للإنزيم المختزل لهيدروكسي ميثيل جلوتاريل كو إنزيم إيه HMG-CoA) ، والمعروف باسم ستاتين، والتي تستخدم لخفض مستويات الكوليسترول (وهو نوع من الدهون) في الدم).</p><p dir="RTL">- اذا كان لديك مستويات منخفضة من البوتاسيوم في الدم (وهي حالة تعرف باسم نقص بوتاسيوم الدم).</p><p dir="RTL">- اذا كان لديك مرض حاد في الكبد أو الكلى.</p><p dir="RTL">- اذا كان لديك عدم انتظام في معدل ضربات القلب.</p><p dir="RTL">&nbsp;إن أقراص <strong>كلاريدار دار الدواء</strong> غير مناسبة للاستخدام في الأطفال دون سن 12 سنة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>كلاريدار دار الدواء</strong></p><p dir="RTL">-إذا كان لديك أي مشاكل في الكبد أو الكلى</p><p dir="RTL">- إذا كنت مصابا بالالتهابات الفطرية ، أو كنت عرضة لها، (مثل القلاع).</p><p dir="RTL">- إذا كنت حاملا أو تقومين بالرضاعة الطبيعية.</p><p dir="RTL">إذا انطبق عليك اي من الحالات السابقة ، استشر طبيبك قبل تناول أقراص<strong> كلاريدار دار الدواء</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التداخلات</strong><strong> </strong><strong>الدوائية</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أخذ</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>المستحضر</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أعشاب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مكملات</strong><strong> </strong><strong>غذائية</strong></p><p dir="RTL">&nbsp;يجب أن لا تتناول أقراص <strong>كلاريدار دار الدواء</strong> إذا كنت تأخذ أي من الأدوية المذكورة في&quot; موانع استعمال &nbsp;<strong>كلاريدار دار الدواء&quot;</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أي من الأدوية التالية حيث أن الجرعة قد تحتاج إلى تعديل أو قد تحتاج إلى إجراء اختبارات بشكل منتظم:</p><p dir="RTL">- ديجوكسين، كوينيدين أو ديسوبيراميد (لعلاج مشاكل القلب).</p><p dir="RTL">- وارفارين (مميع للدم).</p><p dir="RTL">- كاربامازيبين، فالبروات، فينوباربيتال أو فينيتوين (لعلاج الصرع).</p><p dir="RTL">- أتورفاستاتين، روزوفاستاتين ( أدوية مثبطة للإنزيم المختزل لهيدروكسي ميثيل جلوتاريل كو إنزيم إيه HMG-CoA) ، والمعروف باسم ستاتين، والتي تستخدم لخفض مستويات الكولسترول (وهو نوع من الدهون) في الدم).</p><p dir="RTL">- كولشيسين (يؤخذ عادة لعلاج النقرس).</p><p dir="RTL">- ناتيغلينايد، بيوجليتازون، ريباغلينايد، روزيجليتازون أو الأنسولين (التي تستخدم لخفض مستويات السكر في الدم).</p><p dir="RTL">- الثيوفيلين (يستخدم في المرضى الذين يعانون من صعوبات في التنفس مثل الربو).</p><p dir="RTL">- تريازولام، ألبرازولام أو ميدازولام (مهدئات).</p><p dir="RTL">- سيلوستازول (لعلاج ضعف التروية الدموية).</p><p dir="RTL">- أوميبرازول (لعلاج عسر الهضم وقرحة المعدة) ما لم يصرفها الطبيب لك لعلاج عدوى <em>هيليكوباكتر بيلوري</em> المرتبطة بقرحة الاثني عشر.</p><p dir="RTL">- ميثيل بريدنيسولون (من الستيرويدات القشرية).</p><p dir="RTL">- فينبلاستين (لعلاج السرطان).</p><p dir="RTL">- سيكلوسبورين، سيروليميس وتاكروليموس (مثبطات للمناعة).</p><p dir="RTL">- ايترافيرين، ايفافيرنز، نيفيرابين، ريتونافير، زيدوفودين، اتازنفير، ساكوينافير (العقاقير المضادة للفيروسات المستخدمة في علاج فيروس نقص المناعة البشرية).</p><p dir="RTL">- ريفابوتين، ريفامبيسين، ريفابنتين، فلوكونازول، ايتراكونازول ( تستخدم في علاج بعض الالتهابات البكتيرية).</p><p dir="RTL">- تولتيرودين (لعلاج فرط نشاط المثانة).</p><p dir="RTL">- فيراباميل (لعلاج ارتفاع ضغط الدم).</p><p dir="RTL">- سيلدينافيل، فاردينافيل وتادالافيل (لعلاج العجز الجنسي عند الذكور البالغين أو ارتفاع ضغط الدم الشرياني الرئوي (ارتفاع ضغط الدم في الأوعية الدموية في الرئة)).</p><p dir="RTL">- عشبة سانت جون (منتج عشبي لعلاج الاكتئاب).</p><p dir="RTL">لا يتفاعل <strong>كلاريدار دار الدواء </strong>مع حبوب منع الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمل والرضاعة</p><p dir="RTL">إذا كنتِ حامل، تتوقعين الحمل أو تقومين بالرضاعة الطبيعية، اطلبي نصيحة الطبيب قبل تناول أقراص <strong>كلاريدار دار الدواء</strong> . حيت ان مأمونية استخدام <strong>كلاريدار دار الدواء</strong> في الحمل والرضاعة الطبيعية غير معروفة بعد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثير <strong>كلاريدار دار الدواء</strong> على القيادة واستخدام الآلات</p><p>قد تشعر بالدوار أو النعاس عند تناول أقراص <strong>كلاريدار دار الدواء</strong>. إذا شعرت بحدوث هذه الاعراض، لا تقم بالقيادة أو استخدام الالات التي تحتاج الى تركيز بشكل خاص.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تقم بإعطاء هذه الاقراص للأطفال دون سن 12 سنة. سيقوم طبيبك بوصف دواء اخر مناسب لطفلك.</p><p dir="RTL">تناول&nbsp; <strong>كلاريدار دار الدواء</strong> تماما كما وصفه الطبيب لك.. يجب عليك التحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد. الجرعة المعتادة هي:</p><p dir="RTL"><strong>لعلاج التهابات</strong><strong> الصدر، الحلق أو التهابات الجيوب الأنفية والجلد والتهابات الأنسجة اللينة</strong><strong>:</strong></p><p dir="RTL">الجرعة المعتادة من &nbsp;أقراص <strong>كلاريدار دار الدواء</strong> للبالغين والأطفال فوق 12 سنة هي 250 &nbsp;ملغم مرتين يوميا لمدة 6-14يوم، على سبيل المثال قرص 250 ملغم في الصباح وقرص في المساء المبكر. &nbsp;قد يزيد طبيبك الجرعة إلى 500 ملغم مرتين يوميا في حالات العدوى الشديدة.</p><p dir="RTL">يجب ابتلاع &nbsp;أقراص <strong>كلاريدار دار الدواء</strong> مع ما لا يقل عن نصف كوب من الماء.</p><p dir="RTL"><strong>لعلاج عدوى <em>هيليكوباكتر بيلوري</em> المرتبطة بقرحة الاثني عشر</strong><strong> :</strong></p><p dir="RTL">هناك مجموعة من العلاجات الفعالة المتاحة لعلاج عدوى <em>هيليكوباكتر بيلوري ، بحيث تؤخذ </em>أقراص <strong>كلاريدار دار الدواء</strong> بالتزامن مع واحد او اثنين من الأدوية الأخرى .</p><p dir="RTL">تشمل هذه المجموعات ما يلي وتؤخذ عادة لمدة 6 إلى 14 يوما :</p><p dir="RTL">أ)&nbsp; قرص واحد من <strong>كلاريدار دار الدواء</strong> 500 ملغم يؤخذ مرتين يوميا بالتزامن مع أموكسيسيللين ، 1000 ملغم يؤخذ مرتين يوميا بالإضافة إلى لانسوبرازول ، 30 ملغم مرتين يوميا.</p><p dir="RTL">ب)&nbsp; قرص واحد من <strong>كلاريدار دار الدواء</strong> 500 ملغم يؤخذ مرتين يوميا بالتزامن مع ميترونيدازول ، 400 ملغم يؤخذ مرتين يوميا بالإضافة إلى لانسوبرازول ، 30 ملغم مرتين يوميا.</p><p dir="RTL">ج)&nbsp; قرص واحد من <strong>كلاريدار دار الدواء</strong> 500 ملغم يؤخذ مرتين يوميا بالتزامن مع أموكسيسيللين &nbsp;&nbsp;1000 ملغم يؤخذ مرتين يوميا&nbsp; أو ميترونيدازول 400 ملغم يؤخذ مرتين يوميا بالإضافة إلى اوميبرازول 40 ملغم مرة يوميا.</p><p dir="RTL">د)&nbsp; قرص واحد من <strong>كلاريدار دار الدواء</strong> 500 ملغم يؤخذ مرتين يوميا بالتزامن مع أموكسيسيلين&nbsp; 1000 ملغم يؤخذ مرتين يوميا بالإضافة إلى اوميبرازول&nbsp; 20 ملغم مرة يوميا.</p><p dir="RTL">ه)&nbsp; قرص واحد من <strong>كلاريدار دار الدواء</strong> 500 ملغم يؤخذ ثلاث مرات يوميا بالتزامن مع اوميبرازول ، 40 ملغم مرة يوميا.</p><p dir="RTL">قد يختلف&nbsp; العلاج الذي تتلقاه قليلا عن ما سبق. &nbsp;سيقرر طبيبك أي تركيبة علاج هي الأنسب&nbsp; لك. إذا لم تكن متأكدا من الأقراص التي ينبغي عليك تناولها أو مدة العلاج اللازمة ، يرجى استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة</strong><strong> </strong><strong>الزائدة</strong><strong> </strong><strong>من كلاريدار دار الدواء </strong></p><p dir="RTL">اذا تناولت عن طريق الخطأ في يوم واحد أكثر من الكمية التي حددها الطبيب أو إذا ابتلع طفلك عن طريق الخطأ بعض أقراص <strong>كلاريدار دار الدواء</strong> ، اتصل بطبيبك أو قسم الطوارئ في أقرب مستشفى على الفور. من الممكن أن تسبب جرعة زائدة من أقراص <strong>كلاريدار دار الدواء</strong> تقيؤ وآلام في المعدة.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نسيان</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة من</strong><strong> </strong><strong>كلاريدار دار الدواء</strong></p><p dir="RTL">إذا نسيت تناول جرعة&nbsp; من أقراص <strong>كلاريدار دار الدواء</strong>، تناول الجرعة فورا عندما تتذكر. لا تقم بمضاعفة الجرعة التي قام طبيبك بتحديدها.</p><p dir="RTL">لا تتوقف عن تناول أقراص <strong>&nbsp;</strong><strong>كلاريدار دار الدواء</strong>، حتى لو كنت تشعر بتحسن. من المهم أن تستمر بتناول الأقراص طيلة الفترة التي حددها طبيبك، وإلا قد تعود المشكلة مرة أخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن الأدوية الاخرى ؛ إن أقراص<strong> كلاريدار دار الدواء </strong>&nbsp;قد تسبب أعراض جانبية . الا أنها لا تحدث عند كل المرضى . إذا كنت تعاني من أي من الحالات التالية في أي وقت أثناء فترة العلاج ، <strong>يجب وقف العلاج</strong> والاتصال بطبيبك فورا:</p><p dir="RTL">&bull; إسهال شديد أو لفترات طويلة،&nbsp; قد يصاحبه دم أو مخاط. قد يحدث الإسهال خلال شهرين من بدء العلاج بكلاريثرومايسين، وفي هذه الحالة يجب الاتصال بطبيبك.</p><p dir="RTL">&bull; طفح جلدي، صعوبة في التنفس، إغماء أو تورم في الوجه والحلق. تعد هذه علامات حدوث رد فعل تحسسي.</p><p dir="RTL">&bull; اصفرار الجلد (اليرقان)، تهيج الجلد، براز شاحب، بول داكن ، ألم عند لمس البطن،أو فقدان الشهية. قد تكون هذه علامات على عدم عمل الكبد بشكل صحيح.</p><p dir="RTL">&bull; تفاعلات جلدية شديدة مثل ظهور تقرحات في الجلد ،الفم ،الشفتين ،العينين والأعضاء التناسلية (أعراض حدوث رد فعل نادر يسمى متلازمة ستيفنز جونسون / انحلال البشرة السمي).</p><p dir="RTL">&bull; فرفرية هينوخ شونلاين (طفح جلدي يظهر على شكل بقع أرجوانية على الجلد).</p><p dir="RTL">الآثار الجانبية الشائعة لاقراص <strong>كلاريدار دار الدواء</strong> تشمل :</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&bull; صعوبة في النوم</p><p dir="RTL">&bull; تغيرات في حاسة التذوق</p><p dir="RTL">&bull; مشاكل في المعدة مثل الغثيان، التقيؤ، آلام في المعدة، عسر الهضم، الإسهال</p><p dir="RTL">&bull; تغير في الطريقة التي يعمل بها الكبد</p><p dir="RTL">&bull; طفح جلدي</p><p dir="RTL">&bull; زيادة التعرق</p><p dir="RTL">آثار جانبية اخرى أقل شيوعا تشمل :</p><p dir="RTL">&bull; تورم، احمرار أو حكة في الجلد. في بعض الأحيان قد تظهر تقشرات ذات لون بني</p><p dir="RTL">&bull; حب الشباب</p><p dir="RTL">&bull; فرفرية هينوخ شونلاين (الطفح الجلدي الذي يظهر على شكل بقع أرجوانية على الجلد)</p><p dir="RTL">&bull; قلاع (عدوى فطرية) في الفم أو المهبل</p><p dir="RTL">&bull; انخفاض&nbsp; في مستوى خلايا دم معينة (التي يمكن أن تجعل العدوى أكثر احتمالا أو تزيد من خطر حدوث&nbsp; كدمات أو نزيف)</p><p dir="RTL">&bull; فقدان الشهية، حرقة في المعدة، انتفاخ، إمساك، ريح</p><p dir="RTL">&bull; التهاب البنكرياس</p><p dir="RTL">&bull; قلق، عصبية، خمول، تعب، دوخة، رعاش أو اهتزاز</p><p dir="RTL">&bull; ارتباك، فقدان القدرة على التحمل ، هلوسة (رؤية أشياء)، تغير في الإحساس بالواقع أو هلع، اكتئاب، أحلام غير طبيعية أو كوابيس</p><p dir="RTL">&bull; تشنج (نوبات)</p><p dir="RTL">&bull; رنين في الأذنين أو فقدان السمع</p><p dir="RTL">&bull; دوار</p><p dir="RTL">&bull; تنمل</p><p dir="RTL">&bull; تسرب الدم من الأوعية الدموية (النزيف)</p><p dir="RTL">&bull; التهاب الفم أو اللسان</p><p dir="RTL">&bull; تلون اللسان أو الأسنان</p><p dir="RTL">&bull; جفاف الفم</p><p dir="RTL">&bull; فقدان حاسة التذوق او الشم أو حدوث تغير في حاسة الشم</p><p dir="RTL">&bull; آلام المفاصل</p><p dir="RTL">&bull; آلام في العضلات أو فقدان الأنسجة العضلية. إذا كنت تعاني من الوهن العضلي الوبيل (مرض تصبح فيه العضلات ضعيفة وتنهك بسهولة) أو انحلال الربيدات (مرض يسبب انهيار الأنسجة العضلية)، قد يعمل كلاريثرومايسين على تفاقم هذه الأعراض.</p><p dir="RTL">&bull; ألم في الصدر أو تغيرات في معدل ضربات القلب مثل الخفقان</p><p dir="RTL">&bull; تغير في مستويات بعض النواتج المصنوعة في الكبد ، التهاب الكبد أو عدم قدرة الكبد على العمل بشكل صحيح (قد تلاحظ حدوث اصفرار في الجلد ، بول داكن ، براز باهت اللون أو حكة في الجلد)</p><p dir="RTL">&bull; تغيير في مستويات النواتج المصنوعة من قبل الكلى، التهاب كلوي أو عدم قدرة الكلى على العمل بشكل صحيح (قد تلاحظ &nbsp;حدوث تعب ، تورم أو انتفاخ في الوجه، البطن ،الفخذين أو الكاحلين أو مشاكل في التبول)</p><p dir="RTL">&bull; انخفاض في مستويات السكر في الدم أو النواتج الموجودة في الدم. &nbsp;</p><p dir="RTL">&bull; أي تغيير في مستويات بعض الخلايا &nbsp;في الدم.</p><p dir="RTL">استشر طبيبك على الفور في حال حدوث أي من هذه المشاكل أو ظهرت لديك أي أعراض أخرى غير متوقعة أو غير اعتيادية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- يحفظ <strong>كلاريدار دار الدواء</strong> بعيدا عن متناول أيدي الاطفال.</p><p dir="RTL">- يحفظ دون 30 درجة مئوية.</p><p dir="RTL">- لا تستخدم &nbsp;<strong>كلاريدار دار الدواء</strong> بعد تاريخ الانتهاء المذكور على العبوة الخارجية. يدل تاريخ الانتهاء على آخر يوم في الشهر المذكور.</p><p dir="RTL">- يجب عدم التخلص من الادوية في المياه العادمة او النفايات المنزلية. اسأل الصيدلي حول الطريقة السليمة للتخلص من الادوية التي لم تعد بحاجة اليها. سيساعد هذا في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ماهي محتويات <strong>&nbsp;</strong><strong>كلاريدار دار الدواء</strong></p><p dir="RTL">المادة الفعالة:</p><p dir="RTL">يحتوي القرص الواحد من <strong>كلاريدار دار الدواء</strong> على 250 أو 500 ملغم كلاريثرومايسين.</p><p dir="RTL">المواد غير الفعالة الأخرى هي هيدروكسي بروبيل سيليلوز، كروس كارميلوس صوديوم، سيليكا غروية لا مائية، ستيارات المغنيسيوم، سيليلوز دقيق البلورية، هيبروميلوز، ثاني أكسيد التيتانيوم، ماكروغول، تالك و سيميثيكون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- <strong>أقراص كلاريدار دار الدواء 250</strong> هي أقراص مغلفة بيضاء ، دائرية ومحدبة الوجهين عليها رمز (CLR250) على جهة واحدة.</p><p dir="RTL">- <strong>أقراص كلاريدار دار الدواء 500</strong> هي أقراص مغلفة بيضاء ، دائرية ومحدبة الوجهين عليها رمز (CLR500) على جهة واحدة .</p><p dir="RTL">أقراص<strong> كلاريدار دار الدواء</strong> 250 و500 متوفرة في عبوات سعتها 14 قرص. كما تتوفر أقراص كلاريدار دار الدواء 500 في عبوات سعتها 20 قرص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسم وعنوان مالك رخصة التسويق والمصنع</p><p dir="RTL">شركة دار الدواء للتنمية والإستثمار المساهمة المحدودة (ناعور - الأردن)</p><p dir="RTL">هاتف. 132 27 57 (6 962 +)</p><p dir="RTL">فاكس.776 27 57 (6 962 +)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Claridar® Dar Al Dawa 250 mg Tablets.
Claridar® Dar Al Dawa 500 mg Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Claridar® Dar Al Dawa tablet contains 250 or 500 mg clarithromycin.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets.
Claridar® Dar Al Dawa tablets 250 are white, round biconvex film-coated tablets coded 
(CLR250) on one side, plain on the other side. 
Claridar® Dar Al Dawa 500 tablets are white, oval biconvex film coated tablets coded 
(CLR500) on one side, plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Claridar&reg; Dar Al Dawa film-coated tablets are indicated in adults and adolescents 12 years and older for the treatment of the following bacterial infections, when caused by clarithromycin susceptible bacteria (see section 4.4 and 5.1).</p><p>&bull; Acute bacterial exacerbation of chronic bronchitis<br />&bull; Mild to moderate community acquired pneumonia<br />&bull; Acute bacterial sinusitis<br />&bull; Bacterial pharyngitis<br />&bull;Skin infections and soft tissue infections of mild to moderate severity, such as folliculitis, cellulitis and erysipelas</p><p>Clarithromycin film-coated tablets can also be used in appropriate combination with antibacterial therapeutic regimens and an appropriate ulcer healing agent for the eradication of Helicobacter pylori in patients with Helicobacter pylori associated ulcers (see section 4.2).</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dosage of Clarithromycin film-coated Tablets depends on the clinical condition of the patient and has to be defined in any case by the physician.</p><p>Children older than 12 years and adults:<br />&bull; Standard dosage: The usual dose is 250 mg twice daily.<br />&bull; High dosage treatment (severe infections): The usual dose may be increased to 500 mg twice daily in severe infections.<br />&bull; Clinical trials have been conducted using clarithromycin pediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin pediatric suspension (granules for oral suspension).</p><p>Elimination of Helicobacter pyloriin adults:<br />In patients with gastro-duodenal ulcers due to H. pylori infection clarithromycin can be used in a dose of 500 mg twice daily during the eradication therapy in combination with amoxicillin 1000 mg twice daily and omeprazole 20 mg twice daily*.</p><p>Dosage in renal functional impairment:<br />The maximum recommended dosages should be reduced proportionately to renal impairment. In patients with renal impairment with creatinine clearance less than 30 mL/min, the dosage of clarithromycin should be reduced by one-half, i.e. 250 mg once daily, or 250 mg twice daily in more severe infections. Treatment should not be continued beyond 14 days in these patients.</p><p>Duration of therapy:<br />The duration of therapy with Clarithromycin film-coated Tablets depends on the clinical condition of the patient. The duration of therapy has in any case to be determined by the physician. &bull; The usual duration of treatment is 6 to 14 days.<br /><br />&bull; In streptococcus pyogenes (as a beta-haemolytic streptococcal) infections the duration of therapy should be at least 10 days.</p><p>&bull; Combination therapy for the eradication of H. pylori infection,e.g. clarithromycin 500 mg (two 250 mg tablets or one 500 mg tablet) twice daily in combination with amoxicillin 1000 mg twice daily and omeprazole 20 mg twice daily should be continued for 7 days*.</p><p>Method of administration: Clarithromycin film-coated tablets may be given irrespective of food intake. Food does not affect the extent of bioavailability. Food does only slightly delay the onset of absorption of clarithromycin and formation of the 14-hydroxy metabolite.</p><p>* according the publication in Gastroenterology. 1999 Feb; 116(2): 248-53</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clarithromycin is contraindicated in patients with known hypersensitivity to macrolide 
antibiotic drugs or any of its excipients listed in section 6.1. 

Concomitant administration of clarithromycin and any of the following drugs is 
contraindicated: astemizole, cisapride, pimozide, terfenadine as this may result in QT 
prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular 
fibrillation, and torsades de pointe (see section 4.5).

Concomitant administration with ticagrelor or ranolazine is contraindicated. 
Concomitant administration of clarithromycin and ergotamine or dihydroergotamine is 
contraindicated, as this may result in ergot toxicity.
Clarithromycin should not be given to patients with history of QT prolongation or 
ventricular cardiac arrhythmia, including torsades de pointe (see sections 4.4 and 4.5). 
Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors 
(statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the 
increased risk of myopathy, including rhabdomyolysis. (see section 4.5). 
Clarithromycin should not be given to patients with hypokalaemia (risk of prolongation of 
QT-time) 

Clarithromycin should not be used in patients who suffer from severe hepatic failure in 
combination with renal impairment. As with other strong CYP3A4 inhibitors, Clarithromycin should not be used in patients 
taking colchicine. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The physician should not prescribe clarithromycin to pregnant women without carefully weighing the benefits against risk, particularly during the first three months of pregnancy (see section 4.6).</p><p>Caution is advised in patients with severe renal insufficiency (see section 4.2).</p><p>Clarithromycin is principally excreted by the liver. Therefore, caution should be exercised in administering the antibiotic to patients with impaired hepatic function. Caution should also be exercised when administering clarithromycin to patients with moderate to severe renal impairment.</p><p>Cases of fatal hepatic failure (see section 4.8) have been reported. Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products. Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop, such as anorexia, jaundice, dark urine, pruritus, or tender abdomen.</p><p>Pseudomembranous colitis has been reported with nearly all antibacterial agents, including macrolides, and may range in severity from mild to life-threatening. Clostridium difficileassociated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents including clarithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, which may lead to overgrowth of C. difficile. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. Therefore, discontinuation of clarithromycin therapy should be considered regardless of the indication. Microbial testing should be performed and adequate treatment initiated. Drugs inhibiting peristalsis should be avoided.</p><p>There have been post-marketing reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency. Deaths have been reported in some such patients (see section 4.5). Concomitant administration of clarithromycin and colchicine is contraindicated (see section 4.3).</p><p>Caution is advised regarding concomitant administration of clarithromycin and triazolobenzodiazepines, such as triazolam, and midazolam (see section 4.5).</p><p>Caution is advised regarding concomitant administration of clarithromycin with other ototoxic drugs, especially with aminoglycosides. Monitoring of vestibular and auditory function should be carried out during and after treatment</p><p>Due to the risk for QT prolongation, clarithromycin should be used with caution in patients with coronary artery disease, severe cardiac insufficiency, hypomagnesemia, bradycardia (&lt;50 bpm), or when co-administered with other medicinal products associated with QT prolongation (see section 4.5). Clarithromycin must not be used in patients with congenital or documented acquired QT prolongation or history of ventricular arrhythmia (see section 4.3).</p><p>Pneumonia: In view of the emerging resistance of Streptococcus pneumoniae to macrolides, it is important that sensitivity testing be performed when prescribing clarithromycin for community-acquired pneumonia. In hospital-acquired pneumonia, clarithromycin should be used in combination with additional appropriate antibiotics. Skin and soft tissue infections of mild to moderate severity: These infections are most often caused by Staphylococcus aureus and Streptococcus pyogenes, both of which may be resistant to macrolides. Therefore, it is important that sensitivity testing be performed. In cases where beta&ndash;lactam antibiotics cannot be used (e.g. allergy), other antibiotics, such as clindamycin, may be the drug of first choice. Currently, macrolides are only considered to play a role in some skin and soft tissue infections, such as those caused by Corynebacterium minutissimum, acne vulgaris, and erysipelas and in situations where penicillin treatment cannot be used. In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens - Johnson syndrome, and toxic epidermal necrolysis, clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.</p><p>Clarithromycin should be used with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme (see section 4.5).</p><p>HMG-CoA Reductase Inhibitors (statins): Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see section 4.3). Caution should be exercised when prescribing clarithromycin with other statins. Rhabdomyolysis has been reported in patients taking clarithromycin and statins. Patients should be monitored for signs and symptoms of myopathy. In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to prescribe the lowest registered dose of the statin. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered (see 4.5).</p><p>Oral hypoglycemic agents/Insulin: The concomitant use of clarithromycin and oral hypoglycemic agents (such as sulphonylurias) and/or insulin can result in significant hypoglycemia. Careful monitoring of glucose is recommended (see 4.5).</p><p>Oral anticoagulants: There is a risk of serious hemorrhage and significant elevations in International Normalized Ratio (INR) and prothrombin time when clarithromycin is coadministered with warfarin (see section 4.5). INR and prothrombin times should be frequently monitored while patients are receiving clarithromycin and oral anticoagulants concurrently.</p><p>Use of any antimicrobial therapy, such as clarithromycin, to treat H. pylori infection may select for drug-resistant organisms.</p><p>Long-term use may, as with other antibiotics, result in colonization with increased numbers of non-susceptible bacteria and fungi. If superinfections occur, appropriate therapy should be instituted</p><p>. Attention should also be paid to the possibility of cross resistance between clarithromycin and other macrolide drugs, as well as lincomycin and clindamycin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of the following drugs is strictly contraindicated due to the potential for severe drug interaction effects:</p><p>Cisapride, pimozide, astemizole and terfenadine<br />Elevated cisapride levels have been reported in patients receiving clarithromycin and cisapride concomitantly. This may result in QT prolongation and cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation and torsades de pointes. Similar effects have been observed in patients taking clarithromycin and pimozide concomitantly (see section 4.3).</p><p>Macrolides have been reported to alter the metabolism of terfenadine resulting in increased levels of terfenadine which has occasionally been associated with cardiac arrhythmias such as QT prolongation, ventricular tachycardia, ventricular fibrillation and torsades de pointes (see section 4.3). In one study in 14 healthy volunteers, the concomitant administration of clarithromycin and terfenadine resulted in a two to three fold increase in the serum level of the acid metabolite of terfenadine and in prolongation of the QT interval which did not lead to any clinically detectable effect. Similar effects have been observed with concomitant administration of astemizole and other macrolides.</p><p>Ergotamine/dihydroergotamine Postmarketing reports indicate that co-administration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm, and ischemia of the extremities and other tissues including the central nervous system. Concomitant administration of clarithromycin and these medicinal products is contraindicated (see section 4.3).</p><p>HMG-CoA reductase inhibitors (statins) Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see 4.3) as these statins are extensively metabolized by CYP3A4 and concomitant treatment with clarithromycin increases their plasma concentration, which increases the risk of myopathy, including rhabdomyolysis. Reports of rhabdomyolysis have been received for patients taking clarithromycin concomitantly with these statins. If treatment with clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment.</p><p>Caution should be exercised when prescribing clarithromycin with statins. In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to prescribe the lowest registered dose of the statin. Use of a statin that is not dependent on CYP3A metabolism (e.g.fluvastatin) can be considered. Patients should be monitored for signs and symptoms of myopathy.</p><p>Effects of other medicinal products on clarithromycin</p><p>Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carabamazepine, phenobarbital, St. John&#39;s wort) may induce the metabolism of clarithromycin. This may result in sub-therapeutic levels of clarithromycin leading to reduced efficacy. Furthermore it might be necessary to monitor the plasma levels of the CYP3A inducer, which could be increased owing to the inhibition of CYP3A by clarithromycin (see also the relevant product information for the CYP3A4 inhibitor administered). Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis.</p><p>The following drugs are known or suspected to affect circulating concentrations of clarithromycin; clarithromycin dosage adjustment or consideration of alternative treatments may be required.</p><p>Efavirenz, nevirapine, rifampicin, rifabutin and rifapentine</p><p>Strong inducers of the cytochrome P450 metabolism system such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine may accelerate the metabolism of clarithromycin and thus lower the plasma levels of clarithromycin, while increasing those of 14-OHclarithromycin, a metabolite that is also microbiologically active. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers.</p><p>Etravirine</p><p>Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OH-clarithromycin has reduced activity against Mycobacterium avium complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC.</p><p>Fluconazole</p><p>Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers led to increases in the mean steady-state minimum clarithromycin concentration (Cmin) and area under the curve (AUC) of 33% and 18% respectively. Steady state concentrations of the active metabolite 14-OH-clarithromycin were not significantly affected by concomitant administration of fluconazole. No clarithromycin dose adjustment is necessary.</p><p>Ritonavir</p><p>A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200 mg every eight hours and clarithromycin 500 mg every 12 hours resulted in a marked inhibition of the metabolism of clarithromycin. The clarithromycin Cmax increased by 31%, Cmin increased 182% and AUC increased by 77% with concomitant administration of ritonavir. An essentially complete inhibition of the formation of 14-OH-clarithromycin was noted. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function. However, for patients with renal impairment, the following dosage adjustments should be considered: For patients with CLCR 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%. For patients with CLCR &lt;30 mL/min the dose of clarithromycin should be decreased by 75%. Doses of clarithromycin greater than 1 gm/day should not be coadministered with ritonavir.</p><p>Similar dose adjustments should be considered in patients with reduced renal function when ritonavir is used as a pharmacokinetic enhancer with other HIV protease inhibitors including atazanavir and saquinavir (see section below, Bi-directional drug interactions).</p><p>Effect of clarithromycin on other medicinal products</p><p>CYP3A-based interactions</p><p>Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug. Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g. carbamazepine) and/or the substrate is extensively metabolized by this enzyme.</p><p>Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin.</p><p>The following drugs or drug classes are known or suspected to be metabolized by the same CYP3A isozyme: alprazolam, astemizole, carbamazepine, cilostazol, cisapride, cyclosporine, disopyramide, ergot alkaloids, lovastatin, methylprednisolone, midazolam, omeprazole, oral anticoagulants (e.g. warfarin, see 4.4), pimozide, quinidine, rifabutin, sildenafil, simvastatin, sirolimus, tacrolimus, terfenadine, triazolam and vinblastine. Drugs interacting by similar mechanisms through other isozymes within the cytochrome P450 system include phenytoin, theophylline and valproate.</p><p>Antiarrhythmics</p><p>There have been postmarketing reports of torsades de pointes occurring with concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms should be monitored for QT prolongation during co-administration of clarithromycin with these drugs. Serum levels of quinidine and disopyramide should be monitored during clarithromycin therapy.</p><p>There have been post marketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide.</p><p>Oral hypoglycemic agents/Insulin</p><p>With certain hypoglycemic drugs such as nateglinide, and repaglinide, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypolgycemia when used concomitantly. Careful monitoring of glucose is recommended.</p><p>Omeprazole</p><p>Clarithromycin (500 mg every 8 hours) was given in combination with omeprazole (40 mg daily) to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and t1/2 increased by 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when omeprazole was co-administered with clarithromycin.</p><p>Sildenafil, tadalafil, and vardenafil</p><p>Each of these phosphodiesterase inhibitors is metabolized, at least in part, by CYP3A, and CYP3A may be inhibited by concomitantly administered clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil or vardenafil would likely result in increased phosphodiesterase inhibitor exposure. Reduction of sildenafil, tadalafil and vardenafil dosages should be considered when these drugs are co-administered with clarithromycin.</p><p>Theophylline, carbamazepine</p><p>Results of clinical studies indicate there was a modest but statistically significant (p&le; 0.05) increase of circulating theophylline or carbamazepine levels when either of these drugs were administered concomitantly with clarithromycin. Dose reduction may need to be considered.</p><p>Tolterodine</p><p>The primary route of metabolism for tolterodine is via the 2D6 isoform of cytochrome P450 (CYP2D6). However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. A reduction in tolterodine dosage may be necessary in the presence of CYP3A inhibitors, such as clarithromycin in the CYP2D6 poor metabolizer population.</p><p>Triazolobenzodiazepines (e.g. alprazolam, midazolam, triazolam)</p><p>When midazolam was co-administered with clarithromycin tablets (500 mg twice daily), midazolam AUC was increased 2.7-fold after intravenous administration of midazolam and 7-fold after oral administration. Concomitant administration of oral midazolam and clarithromycin should be avoided. If intravenous midazolam is co-administered with clarithromycin, the patient must be closely monitored to allow dose adjustment. The same precautions should also apply to other benzodiazepines that are metabolized by CYP3A, including triazolam and alprazolam. For benzodiazepines which are not dependent on CYP3A for their elimination (temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely. There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.</p><p>Other drug interactions</p><p>Aminoglycosides</p><p>Caution is advised regarding concomitant administration of clarithromycin with other ototoxic drugs, especially with aminoglycosides (see section 4.4).</p><p>Colchicine</p><p>Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When clarithromycin and colchicine are administered together, inhibition of Pgp and/or CYP3A by clarithromycin may lead to increased exposure to colchicine. Patients should be monitored for clinical symptoms of colchicine toxicity (see section 4.4).</p><p>Digoxin</p><p>Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein (Pgp). Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are administered together, inhibition of Pgp by clarithromycin may lead to increased exposure to digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have also been reported in post marketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Serum digoxin concentrations should be carefully monitored while patients are receiving digoxin and clarithromycin simultaneously.</p><p>Zidovudine</p><p>Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Because clarithromycin appears to interfere with the absorption of simultaneously administered oral zidovudine, this interaction can be largely avoided by staggering the doses of clarithromycin and zidovudine to allow for a 4-hour interval between each medication. This interaction does not appear to occur in paediatric HIV-infected patients taking clarithromycin suspension with zidovudine or dideoxyinosine. This interaction is unlikely when clarithromycin is administered via intravenous infusion.</p><p>Phenytoin and Valproate</p><p>There have been spontaneous or published reports of interactions of CYP3A inhibitors, including clarithromycin with drugs not thought to be metabolized by CYP3A (e.g. phenytoin and valproate). Serum level determinations are recommended for these drugs when administered concomitantly with clarithromycin. Increased serum levels have been reported</p><p>Bi-directional drug interactions</p><p>Atazanavir</p><p>Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Co-administration of clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily) resulted in a 2-fold increase in exposure to clarithromycin and a 70% decrease in exposure to 14-OH-clarithromycin, with a 28% increase in the AUC of atazanavir. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function. For patients with moderate renal function (creatinine clearance 30 to 60 mL/min), the dose of clarithromycin should be decreased by 50%. For patients with creatinine clearance &lt;30 mL/min, the dose of clarithromycin should be decreased by 75% using an appropriate clarithromycin formulation. Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors</p><p>Calcium Channel Blockers</p><p>Caution is advised regarding the concomitant administration of clarithromycin and calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) due to the risk of hypotension. Plasma concentrations of clarithromycin as well as calcium channel blockers may increase due to the interaction. Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients taking clarithromycin and verapamil concomitantly.</p><p>Itraconazole</p><p>Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, leading to a bidirectional drug interaction. Clarithromycin may increase the plasma levels of itraconazole, while itraconazole may increase the plasma levels of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged pharmacologic effect. Saquinavir Both clarithromycin and</p><p>saquinavir</p><p>are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Concomitant administration of clarithromycin (500 mg twice daily) and saquinavir (soft gelatin capsules, 1200 mg three times daily) to 12 healthy volunteers resulted in steady-state AUC and Cmax values of saquinavir which were 177% and 187% higher than those seen with saquinavir alone. Clarithromycin AUC and Cmax values were approximately 40% higher than those seen with clarithromycin alone. No dose adjustment is required when the two drugs are co-administered for a limited time at the doses/formulations studied. Observations from drug interaction studies using the soft gelatin capsule formulation may not be representative of the effects seen using the saquinavir hard gelatin capsule. Observations from drug interaction studies performed with saquinavir alone may not be representative of the effects seen with saquinavir/ritonavir therapy. When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy category: C</p><p>Pregnancy</p><p>The safety of clarithromycin for use during pregnancy has not been established. Based on variable results obtained from studies in mice, rats, rabbits and monkeys, the possibility of adverse effects on embryofoetal development cannot be excluded. Therefore, use during pregnancy is not advised without carefully weighing the benefits against risk.</p><p>Lactation</p><p>The safety of clarithromycin for use during breast feeding of infants has not been established. Clarithromycin is excreted into human breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive or use machines. The potential for dizziness, vertigo, confusion and disorientation, which may occur with the medication, should be taken into account before patients drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile</p><p>The most frequent and common adverse reactions related to clarithromycin therapy for both adult and pediatric populations are abdominal pain, diarrhea, nausea, vomiting and taste perversion. These adverse reactions are usually mild in intensity and are consistent with the known safety profile of macrolide antibiotics (see section b of section 4.8).</p><p>There was no significant difference in the incidence of these gastrointestinal adverse reactions during clinical trials between the patient population with or without preexisting mycobacterial infections</p><p>. b. Tabulated summary of adverse reactions</p><p>The following table displays adverse reactions reported in clinical trials and from postmarketing experience with clarithromycin immediate-release tablets. The reactions considered at least possibly related to clarithromycin are displayed by system organ class and frequency using the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100) and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed</p><p>. Infections and infestations</p><p>Uncommon: candidiasis, vaginal infection<br />not known: Pseudomembranous colitis, erysipelas</p><p>Blood and the lymphatic system disorders<br />Uncommon: Leukopenia, neutropenia, eosinophilia<br />Not known: Agranulocytosis, thrombocytopenia</p><p>Immune system disorders<br />* Uncommon: hypersensitivity<br />Not known: Anaphylactic reaction, angioedema</p><p>Metabolism and nutrition disorders<br />Uncommon: Anorexia, decreased appetite</p><p>Psychiatric disorders<br />Common: Insomnia<br />Uncommon: Anxiety<br />Not known: Psychotic disorder, confusional state, depersonalisation, depression, disorientation, hallucination, abnormal dreams</p><p>Nervous system disorders<br />Common: Dysgeusia, headache, taste perversion<br />Uncommon: Dizziness, somnolence# , tremor<br />Not known: Convulsion, ageusia, parosmia, anosmia , paraesthesia</p><p>Ear and labyrinth disorders<br />Uncommon: Vertigo, impaired hearing, tinnitus<br />Not known: deafness Cardiac disordersUncommon: electrocardiogram QT prolonged# ,<br />Not known: Torsade de Pointes# , ventricular tachycardia#</p><p>Vascular disorders<br />Not known: Hemorrhage# Gastrointestinal disorders<br />Common: Diarrhea*, vomiting, abdominal pain, nausea, dyspepsia,<br />Uncommon: Gastritis, stomatitis, glossitis, abdominal distension, constipation, dry mouth, eructation, flatulence,<br />Not known: Pancreatitis, tongue discolouration, tooth discoloration</p><p>Hepato-biliary disorders<br />Common: Liver function test abnormal<br />Uncommon: Cholestasis, hepatitis, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased Not known: Hepatic failure*, jaundice hepatocellular</p><p>Skin and subcutaneous tissue disorders<br />Common: Rash, hyperhidrosis<br />Uncommon: pruritus, urticaria<br />Not known: Stevens-Johnson syndrome*, toxic epidermal necrolysis*, drug rash with eosinophilia and systemic symptoms (DRESS), acne</p><p>Musculoskeletal, connective tissue and bone disorders<br />Not known: Myopathy</p><p>Renal and urinary disorders<br />Not known: Renal failure, interstitial nephritis</p><p>General disorders and administration site conditions<br />Uncommon: Malaise, asthenia, chest pain, chills, fatigue</p><p>Investigations<br />Uncommon: blood alkaline phosphatase increased, blood lactate dehydrogenase increased,<br />Not known: International normalised ratio increased# , prolongation of prothrombin time# , urine color abnormal *&hellip; see a) #&hellip; see b)</p><p>c. Description of selected adverse reactions</p><p>Injection site phlebitis, injection site pain, vessel puncture site pain, and injection site inflammation are specific to the clarithromycin intravenous formulation. In some of the reports of rhabdomyolysis, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol (see section 4.3 and 4.4).</p><p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested (see section 4.5).</p><p>There have been rare reports of clarithromycin ER tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times. In several reports, tablet residues have occurred in the context of diarrhea. It is recommended that patients who experience tablet residue in the stool and no improvement in their condition should be switched to a different clarithromycin formulation (e.g. suspension) or another antibiotic. Special population: Adverse Reactions in Immunocompromised Patients (see section e)</p><p>d. Paediatric populations</p><p>Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin paediatric suspension. There are insufficient data to recommend a dosage regimen for use of the clarithromycin IV formulation in patients less than 18 years of age. Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.</p><p>e. Other special populationsImmunocompromised patients In AIDS and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse events possibly associated with clarithromycin administration from underlying signs of Human Immunodeficiency Virus (HIV) disease or intercurrent illness. In adult patients, the most frequently reported adverse reactions by patients treated with total daily doses of 1,000 mg and 2,000 mg of clarithromycin were: nausea, vomiting, taste perversion, abdominal pain, diarrhea, rash, flatulence, headache, constipation, hearing disturbance, and Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvate Transaminase (SGPT) elevations. Additional low-frequency events included dyspnoea, insomnia and dry mouth. The incidences were comparable for patients treated with 1,000 mg and 2,000 mg, but were generally about 3 to 4 times as frequent for those patients who received total daily doses of 4,000 mg of clarithromycin. In these immunocompromised patients, evaluations of laboratory values were made by analysing those values outside the seriously abnormal level (i.e. the extreme high or low limit) for the specified test. On the basis of these criteria, about 2% to 3% of those patients who received 1,000 mg or 2,000 mg of clarithromycin daily had seriously abnormal elevated levels of SGOT and SGPT, and abnormally low white blood cell and platelet counts. A lower percentage of patients in these two dosage groups also had elevated Blood Urea Nitrogen levels. Slightly higher incidences of abnormal values were noted for patients who received 4,000 mg daily for all parameters except White Blood Cell.</p><p>To report any side effects:<br /> National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: + 966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340<br />o Toll free phone: 8002490000<br />o Email: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports indicate the ingestion of large amounts of clarithromycin can be expected to produce gastrointestinal symptoms. One patient who had a history of bipolar disorder ingested eight grams of clarithromycin and showed altered mental status, paranoid behaviour, hypokalaemia and hypoxaemia.</p><p>Adverse reactions accompanying overdosage should be treated by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum levels are not expected to be appreciably affected by hemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>General properties</u></em></p><p>Pharmacological-therapeutical group:</p><p>ATC Code J01FA09. Clarithromycin is a semi-synthetic derivative of erythromycin A.</p><p><em><u>Mechanism of action:</u></em></p><p>Clarithromycin exerts its antibacterial action by binding to the 50s ribosomal sub-unit of susceptible bacteria and suppresses protein synthesis. It is highly potent against a wide variety of aerobic and anaerobic gram-positive and gram-negative organisms. The minimum inhibitory concentrations (MICs) of clarithromycin are generally two-fold lower than the MICs of erythromycin.</p><p>The 14-hydroxy metabolite of clarithromycin also has antimicrobial activity. The MICs of this metabolite are equal or two-fold higher than the MICs of the parent compound, except for H influenzae where the 14-hydroxy metabolite is two-fold more active than the parent compound.</p><p><em><u>Breakpoints</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:553px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>NCCLS*</p></td><td colspan="2" style="vertical-align:top"><p>BSAC**</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>susceptible</p><p>(&micro;g/ml)</p></td><td style="vertical-align:top"><p>resistant</p><p>(&micro;g/ml)</p></td><td style="vertical-align:top"><p>susceptible</p><p>(&micro;g/ml)</p></td><td style="vertical-align:top"><p>resistant</p><p>(&micro;g/ml)</p></td></tr><tr><td style="vertical-align:top"><p>Staphylococcus spp.</p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&ge; 8</p></td><td style="vertical-align:top"><p>&le; 0.5</p></td><td style="vertical-align:top"><p>&ge; 1</p></td></tr><tr><td style="vertical-align:top"><p>Haemophilus spp.</p></td><td style="vertical-align:top"><p>&le; 8</p></td><td style="vertical-align:top"><p>&ge; 32</p></td><td style="vertical-align:top"><p>&le; 0.5</p></td><td style="vertical-align:top"><p>&ge; 32</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus pneumoniae</p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&ge; 1</p></td><td style="vertical-align:top"><p>&le; 0.5</p></td><td style="vertical-align:top"><p>&ge; 1</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus spp. other than S. pneumoniae</p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&ge; 1</p></td><td style="vertical-align:top"><p>&le; 0.5</p></td><td style="vertical-align:top"><p>&ge; 1</p></td></tr><tr><td style="vertical-align:top"><p>Helicobacter pylori</p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&ge; 1</p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>&ge; 2</p></td></tr></tbody></table><p>* National Committee on Clinical Laboratory Standards, in 2001</p><p>** British Society for Antimicrobial Chemotherapy</p><p><em><u>Susceptibility</u></em></p><p>The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. This information gives only an appropriate guidance on the probabilities whether micro-organisms will be susceptible to clarithromycin or not. As far as applicable the information on the European range of acquired resistance for the individual micro-organism is indicated in brackets.</p><table border="1" cellspacing="0" cellpadding="0" style="width:553px"><tbody><tr><td style="vertical-align:top"><p><em>Species</em></p></td><td style="vertical-align:top"><p>Frequency of resistance ranges in EU (if &gt; 10%) (extreme values)<sup>1)</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gram-positive aerobes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Staphylococcus aureus</p><p>(methicillin-susceptible)</p></td><td style="vertical-align:top"><p>(18.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus pyogenes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus agalactiae</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Group C, F, G Streptococci</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus pneumoniae</p></td><td style="vertical-align:top"><p>(37.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Gram-negative aerobes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Haemophilus infuenzae</p></td><td style="vertical-align:top"><p>(13.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Helicobacter pylori</p></td><td style="vertical-align:top"><p>(14%)</p></td></tr><tr><td style="vertical-align:top"><p>Legionalla spp.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Moraxella catarrhalis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neisseria gonorrhoeae</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaerobes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Bacteroides spp.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clostridum spp. other than C. difficile</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fusobacterium spp.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Peptococcus/Peptostreptococcus spp.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Others</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Chlamydia trachomatis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Chlamydia pneumoniae</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mycoplasma pneumoniae</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Insusceptible</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gram-positive aerobes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Enterococcus spp.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Staphylococcus aureus</p><p>(Erythromycin resistant or MRSA)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Others</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mycobacterium tuberculosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>MRSA - methicillin resistant <em>Staphylococcus aureus</em></p><p><sup>1)</sup> Frequencies of resistance ranges calculated on NCCLS breakpoints</p><p><em><u>Other information</u></em></p><p>Susceptibility and resistance of <em>Streptococcus pneumoniae</em> and <em>Streptococcus</em> spp. to clarithromycin can be predicted by testing erythromycin.</p><p>The mechanisms of acquired resistance in macrolides are: efflux of drug by an active pump mechanism, inducible or constitutive production of a methylase enzyme that modifies the ribosomal target, hydrolysis of macrolides by esterases, chromosomal mutations that alter a 50 S ribosomal protein. Cross-resistance between clarithromycin and other macrolides and clindamycin and lincomycin may therefore occur. Methicillin-resistant and oxacillin-resistant staphylococci (MRSA) and penicillin-resistant Streptococcus pneumoniae are resistant to all currently available Beta-lactam antibiotics and macrolides such as clarithromycin.</p><p>Most available clinical experience from controlled randomised clinical trials indicate that clarithromycin 500 mg twice daily in combination with another antibiotic e.g. amoxicillin or metronidazole e.g. omeprazole (given at approved levels) for 7 days achieve &gt; 80% H. pylori eradication rate in patients with gastro-duodenal ulcers. As expected, significantly lower eradication rates were observed in patients with baseline metronidazole-resistant H. pylori isolates. Hence, local information on the prevalence of resistance and local therapeutic guidelines should be taken into account in the choice of an appropriate combination regimen for H. pylori eradication therapy. Furthermore, in patients with persistent infection, potential development of secondary resistance (in patients with primary susceptible strains) to an antimicrobial agent should be taken into the considerations for a new treatment regimen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Absorption:</u></em></p><p>Clarithromycin is rapidly and well absorbed from the gastrointestinal tract &ndash; primarily in the jejunum - after oral administration. Due to its chemical structure (6-O-Methylerythromycin) clarithromycin is quite resistant to degradation by stomach acid. Serum levels of 1 &ndash; 2 &micro;g/ml clarithromycin were observed in adults after oral administration of 250 mg twice daily. After administration of 500 mg clarithromycin twice daily serum levels of 2,8 &micro;g/ml were obtained.</p><p>After administration of 250 mg clarithromycin twice daily the pharmacological active 14-hydroxy metabolite attains peak plasma concentrations of 0,6 &micro;g/ml.</p><p><em><u>Distribution:</u></em></p><p>Clarithromycin gives good penetration into different compartments. Therapeutic drug levels exceeding the minimum inhibitory levels for common pathogens can be rapidly achieved. Clarithromycin provides tissue concentrations that are several times higher than the circulating drug levels. Increased levels have been found in both tonsillar and lung tissue. Clarithromycin also penetrates the gastric mucus.</p><p>Clarithromycin is 80% bound to plasma proteins at therapeutic levels.</p><p><em><u>Serum half-life:</u></em></p><p>The serum half-life of the active 14-(R)-hydroxy metabolite ranges between 5 to 6 hours.</p><p><em><u>Biotransformation and elimination:</u></em></p><p>Clarithromycin is rapidly and extensively metabolised in the liver. Metabolism involves mainly N-dealkylation, oxidation and stereospecific hydroxylation at position C 14.</p><p>After oral administration of radioactive clarithromycin 70 - 80% of the radioactivity was found in the faeces. Approximately 20 -30% of clarithromycin is collected as the unchanged parent molecule in the urine. This proportion is increased when the dose is increased. Renal insufficiency increases clarithromycin levels in plasma, if the dose is not decreased.</p><p>The pharmacokinetics of clarithromycin are non linear. This is an indication for a saturation of hepatic metabolism at high doses; however, steady state is attained within 2 days of dosing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In acute mouse and rat studies, the median lethal dose was greater than the highest feasible dose for administration (5g/kg). In repeated dose studies, toxicity was related to dose, duration of treatment and species. Dogs were more sensitive than primates or rats. The major clinical signs at toxic doses included emesis, weakness, reduced food consumption and weight gain, salivation, dehydration and hyperactivity. In all species the liver was the primary target organ at toxic doses. Hepatotoxicity was detectable by early elevations of liver function tests. Discontinuation of the drug generally resulted in a return to or toward normal results. Other tissues less commonly affected included the stomach, thymus and other lymphoid tissues and the kidneys. At near therapeutic doses conjunctival injection and lacrimation occurred only in dogs. At a massive dose of 400mg/kg/day, some dogs and monkeys developed corneal opacities and/or oedema. Fertility and reproduction studies in rats have shown no adverse effects. Teratogenicity studies in rats (Wistar (p.o.) and Spraque-Dawley (p.o. and i.v.)), New Zealand White rabbits and cynomolgus monkeys failed to demonstrate any teratogenicity from clarithromycin. However, a further similar study in Sprague-Dawley rates indicated a low (6%) incidence of cardiovascular abnormalities which appeared to be due to spontaneous expression of genetic changes. Two mouse studies revealed a variable incidence (3-30%) of cleft palate and embryonic loss was seen in monkeys but only at dose levels which were clearly toxic to the mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxyl propyl cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, microcrystalline cellulose microcrystalline, hypromellose, titanium dioxide, macrogol, talc, simethicone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Claridar&reg; Dar Al Dawa 250 Film Coated Tablets are packed in PVC/PVDC aluminum blisters in packs of 14 and enclosed in a carton along with an insert.Claridar&reg; Dar Al Dawa 500 Film Coated Tablets are packed in in PVC/PVDC aluminum blisters in packs of 14 and 20 and they enclosed in a carton along with an insert. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dar Al Dawa Development & Investment Co. Ltd.
P.O.Box 9364 
Na’ur - Jordan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17/02/2015

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>